Scientific research and funding

In total, SCT has invested over £3 million in skeletal cancer research. Our funding has contributed to numerous projects, including:

The development of a growing prosthesis for children – removal of the primary tumour usually diminishes growth in the limb. This prosthesis allows the operated limb to maintain length without further surgery.
A genomic analysis of osteosarcoma – this study, carried out with the Sanger Institute, has allowed analysis of the genetic structure of these tumours, opening potential avenues for novel and personalised treatments.
The first UK project to utilise Raman Spectroscopy – to investigate the microstructure of Osteosarcoma.
Various studies on the fixation of implants to host bone – total hip and knee implants last around 20 years on average. Our patients ideally need their prostheses to last for life, hence the importance of this work.
 
The establishment of an in-vitro three-dimensional model of osteosarcoma to predict chemotherapy responders and non-responders.
The first UK trial to utilise Photodynamic Therapy (PDT) intraoperatively to eliminate the risk of local tumour recurrence following major reconstructive surgery.
The opening of the new Stanmore building now at the Royal National Orthopaedic Hospital in March 2019. SCT was also able to fund equipment for the adult acute ward patient rooms.
A supporter for patients and families affected by Ollier’s Disease and Maffucci Syndrome – two chronic conditions requiring multiple operations and risk of malignancy.
 
 

Individual patient support

The welfare of patients and their families is paramount to us at SCT.

 

The ‘Live Life to the Full’ campaign

Over a decade ago we became aware that external prostheses for those children who had undergone amputation were woeful.

In response, we established a Live Life to the Full campaign to supply these young people with prostheses which would allow them to maximise their potential. The prostheses provided included C-Legs and running blades.

Due in part to charity and patient pressure, the Department of Health now supplies children with prosthetic legs, but we continue to help with both prostheses and equipment when indicated.

 

Coping after intensive treatment

Although survival is the first priority for patients diagnosed with skeletal cancer, it can come at a physical and emotional cost.

Many of our patients will have limb-salvage surgery after an intensive course of chemotherapy. For some of our patients, they not only receive a cancer diagnosis, they also face life as an amputee. We are committed to ensuring that surgical interventions are safer.

But cancer doesn’t stop when treatment finishes.

We’re also committed to ensuring that our patients, their families and friends receive the emotional support they need.

 
 

What next / now for SCT?

The charity has achieved a great deal since its inception 25 years ago, but we still need additional funding in our efforts to improve both the survival and quality of life of these young people. The Skeletal Cancer Trust relies entirely on donations. All money donated to SCT helps patients with bone cancer both now and in the future.

 
 
 

Research →

SCT understands the vital importance of research into bone cancers. Without research, no progress can be made in reducing the traumatic impact these diseases have on patients, their families and friends.

Apply for support →

SCT has raised £2.5m over the last 10 years, thanks to our many donors, supporters and fundraisers. To apply for a support grant, please contact us here.

Where the money goes →

All money raised has been committed to SCT’s many projects and spent wisely in helping bone cancer patients, both now and in the future.